PLC () has filed a new patent application for its CDX antibody.

It covers its use in conditioning patients for bone marrow transplant and its deployment in a number of hard-to-treat blood borne diseases, including acute myeloid leukaemia (AML).

On the latter, the application covers the composition sequences of newly-discovered monoclonal antibodies against a target protein expressed on the surface of hematopoietic stem cells of certain types of leukaemia.

“Filing this patent is an important development and further solidifies Hemogenyx’s leadership position in the development of new methods of bone marrow transplantation and treatments for blood cancers such as AML, acute lymphoblastic leukemia and possibly others,” said Hemogenyx chief executive, Dr Vladislav Sandler.

“The antibody we are developing, CDX, should, if successful, provide a new, effective and safe method of conditioning patients for bone marrow transplants, and has the potential to be a superior pharmaceutical for the treatment of blood cancers, for which survival rates are currently very poor.”